secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001140361-23-000743
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed updates pipeline: ARIKAYCE 2023 rev guidance $285-300M; brensocatib CF data positive
--------------------------------------------------------------------------------

- ARIYACE global revenue 2022 up ~30% YoY; 2023 guidance $285-300M.
- Phase 2 brensocatib in CF showed dose-dependent NSP inhibition; 65 mg cohort not needed.
- Phase 3 ASPEN (bronchiectasis) blended blinded event rate 1.12-1.15 events/patient/year; enrollment on track for Q1 2023.
- Post-marketing ARISE trial had 15% treatment discontinuation rate, less than half of pivotal CONVERT.
- Early-stage pillars target musculoskeletal, CNS, ocular, rheumatologic; first IND expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036123000743/0001140361-23-000743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036123000743/brhc10046302_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-000743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer